Medicare tightens rules on diagnostic tests—but who pays the cost?
H.R. 3092 — Electrodiagnostic Medicine Patient Protection and Fraud Elimination Act of 2025 · Filed by Pete Sessions (R-TX) · 2 cosponsors · Introduced Apr 30, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicare to pay for electrodiagnostic services (nerve conduction studies and needle electromyography tests) only if they are performed at facilities that meet specific accreditation and quality standards, effective 3–4 years after enactment. The bill mandates that facilities have quality assurance programs, use approved equipment, employ trained personnel, and interpret results on-site in real time. The Secretary of Health and Human Services must designate accrediting organizations and establish an advisory committee to oversee standards and combat fraud.
Why we flagged it
The bill's core mechanism is a regulatory mandate requiring accreditation and quality standards for electrodiagnostic service providers under Medicare. While framed as fraud elimination, it functions primarily as a quality-assurance and facility-consolidation measure.
What the text implies
- The 3–4 year implementation window may allow incumbent accredited facilities to establish market dominance before smaller competitors can meet standards, potentially reducing provider competition.
- Accreditation requirements may disproportionately burden rural and safety-net providers with limited resources, reducing geographic access to these diagnostic services.
The full analysis lists 4 implications of this text.
Who stands to gain
Accreditation organizations (newly designated gatekeepers); Large, well-capitalized diagnostic facilities able to meet accreditation standards; Diagnostic equipment manufacturers (devices must meet specified technical standards)